These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11856508)

  • 1. [Arsenic trioxide for the treatment of medium and advanced primary liver cancer].
    Qian J; Qin S; He Z; Wang L; Chen Y; Shao Z; Liu X
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):63. PubMed ID: 11856508
    [No Abstract]   [Full Text] [Related]  

  • 2. [Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer].
    Qian J; Qin S; He Z
    Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):487-9. PubMed ID: 11859717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].
    Qu FL; Hao XZ; Qin SK; Liu JW; Sui GJ; Chen Q; Qu T; Zhang HP; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):697-701. PubMed ID: 22340053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 5. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
    Ofran Y; Avivi I; Gesundheit B; Or R; Rowe JM; Zuckerman T
    Am J Hematol; 2007 Apr; 82(4):332-3. PubMed ID: 17080434
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 7. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 8. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
    Müller E; Seidel MG; Lackner H; Dworzak M; Urban C
    Klin Padiatr; 2013 May; 225(3):172-3. PubMed ID: 23625686
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
    Nouri K; Ricotti CA; Bouzari N; Chen H; Ahn E; Bach A
    J Drugs Dermatol; 2006 Feb; 5(2):182-5. PubMed ID: 16485889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes zoster during treatment with arsenic trioxide.
    Tanvetyanon T; Nand S
    Ann Hematol; 2004 Mar; 83(3):198-200. PubMed ID: 15064871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
    N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Novoseven for arsenic trioxide-induced bleeding in PML.
    Alimoghaddam K; Ghavamzadeh A; Jahani M
    Am J Hematol; 2006 Sep; 81(9):720. PubMed ID: 16804937
    [No Abstract]   [Full Text] [Related]  

  • 16. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.
    Lin CC; Hsu C; Hsu CH; Hsu WL; Cheng AL; Yang CH
    Invest New Drugs; 2007 Feb; 25(1):77-84. PubMed ID: 16937079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delicious poison: arsenic trioxide for the treatment of leukemia.
    Kwong YL; Todd D
    Blood; 1997 May; 89(9):3487-8. PubMed ID: 9129058
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antileukemic].
    Inomata T; Sunami K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():191-4. PubMed ID: 25831750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.